tag:blogger.com,1999:blog-36768584.post3456472896254610383..comments2024-03-03T18:49:34.382-05:00Comments on Omics! Omics!: UK CMA's Write-up of PacBio Acquisition by Illumina Makes for XXX Reading; Clearly They Believe XXX and XXXKeith Robisonhttp://www.blogger.com/profile/04765318239070312590noreply@blogger.comBlogger5125tag:blogger.com,1999:blog-36768584.post-58320704764252210372022-04-09T07:51:25.971-04:002022-04-09T07:51:25.971-04:00as we see given by the current share price = merge...as we see given by the current share price = merger price, the government has in fact potentially destroyed a business, not created a competitor. Meddling by government is seldom a good idea.Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-36768584.post-18198992021050480272019-07-25T13:44:00.075-04:002019-07-25T13:44:00.075-04:00Nice post Keith. Paragraph 107 is the most interes...Nice post Keith. Paragraph 107 is the most interesting redaction for me. Illumina appear to have requested redaction on their biggest competitor, while PacBio are happy to state ONT.<br /><br />Oh to be able to read paragraphs 117-120 in full!<br /><br />I've my own synopsis over at CoreGenomics: http://enseqlopedia.com/2019/07/will-illumina-succeed-buying-pacbio/James@cancerhttps://www.blogger.com/profile/02825715598810395734noreply@blogger.comtag:blogger.com,1999:blog-36768584.post-69976992028898484702019-07-23T13:11:10.583-04:002019-07-23T13:11:10.583-04:00The 100M breakup fee will help Pacbio keep afloat ...The 100M breakup fee will help Pacbio keep afloat long term. Quarterly loss != quarterly cash burn. Pacbio has on average burned about 60M of cash a year. They currently have $80M in the bank and will get another $100M if the deal falls apart. This gives them $180M cash in the bank which will last them 3 years (2022). That's assuming Sequel II doesn't boost revenues and reduce the burn rate. I suspect the 8x reduction in sequencing costs with the Sequel II should help grow revenues substantially.johnnoreply@blogger.comtag:blogger.com,1999:blog-36768584.post-75397274636860722522019-07-23T05:26:41.189-04:002019-07-23T05:26:41.189-04:00Thanks for the post. It seems like that illumina i...Thanks for the post. It seems like that illumina is quite confident with its dominance in both technology and marketing field, and Pacbio may be far more vulnerable in this transaction than we thought. And I'm so worried for the former Sequel buyers, and I remember once you said, Pacbio had to become a company with a long-term future.Liang Zonghttps://www.blogger.com/profile/17673724918573718618noreply@blogger.comtag:blogger.com,1999:blog-36768584.post-26971375909106046652019-07-22T19:54:29.572-04:002019-07-22T19:54:29.572-04:00Thank you for posting this.
It kind of reminds me...Thank you for posting this.<br /><br />It kind of reminds me of the FDA approval documents for Restasis (although the scissors icon does seem more fashionable than what I assume was white-out and pen):<br /><br />https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-023_Restasis.cfm<br /><br />In contrast, the material is still a lot to go through, but I was able to read the full contents for the Celexa FDA approval (for what is now the generic citalopram that I take, for less than $3 a month):<br /><br />https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020822a.cfmcdwSciencehttps://www.blogger.com/profile/11895261662921346808noreply@blogger.com